Education

• Professor, Internal Medicine
• B.S., The College of William and Mary, 1981
• D.V.M., Cornell University, 1986
• Internship and Residency in Small Animal Internal Medicine, The Animal Medical Center, NY, NY, 1986-1989
• Diplomate, ACVIM, 1991
• Ph.D., Pharmacology, Cornell University, 1997
• Diplomate, ACVCP, 1998

Research

Dr. Trepanier's research area is genetically determined differences in xenobiotic detoxification and their effect on the individual risk of  toxicity. The major focus of her laboratory is the effect of variability in drug reduction pathways (cytochrome b5 and its reductase, and antioxidant pathways) and on the outcome of sulfonamide hypersensitivity reactions in dogs and humans, and on carcinogenesis from arylamines such as 4-aminobiphenyl and PhIP.

Responsibilities

Section head, Small Animal Internal Medicine

Director, Clinician Scientist Training Programs

Clinical Interests

Clinical pharmacology and therapeutics, particularly adverse drug reactions and drug interactions; Small animal internal medicine, particularly hematology and hepatology.

Graduate Training

Member, Graduate faculties of Pharmaceutical Sciences, Molecular and Environmental Toxicology, and Comparative Biosciences

Video: Turning a Clinical Question into a Testable Hypothesis

Recent Publications

Lavergne SN, Drescher NJ, Trepanier LA. Anti-myeloperoxidase and anti-cathepsin G antibodies in sulfonamide hypersensitivity Clin Exp Allergy 38: 199-207, 2008.

Lavergne SN, Trepanier LA. Anti-platelet antibodies in a natural animal model of sulphonamide-associated thrombocytopenia Platelets 18: 595-604, 2007.

Kurian JR, Longlais BJ, Trepanier LA. Discovery and characterization of a cytochrome b₅ variant in humans with impaired hydroxylamine reduction capacity. Pharmacogenetics and Genomics 17: 497-603, 2007.

Kurian JR, Chin NA, Longlais BJ, Hayes KL, Trepanier LA. Reductive detoxification of arylhydroxylamine carcinogens by human NADH cytochrome b₅ reductase and cytochrome b₅. Chem Res Toxicol 19: 1366-73, 2006.

Lavergne SN, Danhof R, Volkman E, Trepanier LA. Association of drug-protein adducts and anti-drug antibodies in a clinical model of sulfonamide hypersensitivity. Clin Exp Allergy  36: 907-15, 2006.

Lavergne SN, Kurian JR, Bajad SU, Maki JE, Yoder AE, Guzinski MV, Graziano FM, Trepanier LA. Roles of endogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso. Toxicology 222: 25-36, 2006.

Saulter JY, Kurian JR, Trepanier LA, Tidwell RR, Bridges AS, Boykin DW, Stephens CE, Anbazhagan M, Hall JE. Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase. Drug Metab Disp 33:1886-1893, 2005.

Trepanier LA, Bajad SU, Kurian JR. Evaluation of the cytochrome b₅ / cytochrome b₅ reductase pathway Current Protocols in Toxicology (invited review) 4.16.1-4.16.17, 2005.

Lavergne SN, Volkmann EM, Maki JE, Yoder AR, Trepanier LA. Evaluation of the clinical, immunologic, and biochemical effects of sulfamethoxazole-nitroso administration to dogs: a pilot study. Toxicology 208: 63-72, 2005.

Kurian JR, Bajad S, Miller JL, Chin N, Trepanier LA. NADH cytochrome b₅ reductase and cytochrome b₅ catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J Pharmacol Exp Ther 311:1171-8, 2004.

Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Ther 27: 129-138, 2004.